Abstract
Background: Non-small cell lung cancer is the leading cancer-related cause of death.
Objective: We review the latest therapies for NSCLC with EGFR and ELM4-ALK mutations as well as the most relevant studies and promising patents.
Method: A literature search of PubMed database was carried out to identify recent Clinical Trials using EGFR therapies and novel patents involving diagnosis and therapies on NSCLC. We conducted a search to find new therapy strategies, new biomarkers, and selected five patents we find relevant.
Results: Over the last few years, identification of cancer harboring epidermal growth factor receptor mutations (EGFR) or chromosomal rearrangements of anaplastic lymphoma kinase (ALK) led to new ways in classifying and treating NSCLC. On the other hand, acquired resistance are a constantly challenge in the management of patients with these mutations and new drugs options are in development to improve and amplify treatment strategies.
Conclusions: Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes. To understand the disease molecular profile is mandatory to define the best approach for each patient.
Keywords: Afatinib, EGFR, ELM4-ALK, erlotinib, geftinib, non-small cell lung cancer, osimertinib, patent.
Recent Patents on Anti-Cancer Drug Discovery
Title:EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer
Volume: 11 Issue: 4
Author(s): Ramon Andrade De Mello*, Davi J. J. Liu, Pedro N. Aguiar and Hakaru Tadokoro
Affiliation:
- Department of Biomedical Sciences and Medicine, University of Algarve, Campus de Gambelas, Ala nascente, Edifício 7, 3º Andar, 8005-139, Faro, Portugal.,Portugal
Keywords: Afatinib, EGFR, ELM4-ALK, erlotinib, geftinib, non-small cell lung cancer, osimertinib, patent.
Abstract: Background: Non-small cell lung cancer is the leading cancer-related cause of death.
Objective: We review the latest therapies for NSCLC with EGFR and ELM4-ALK mutations as well as the most relevant studies and promising patents.
Method: A literature search of PubMed database was carried out to identify recent Clinical Trials using EGFR therapies and novel patents involving diagnosis and therapies on NSCLC. We conducted a search to find new therapy strategies, new biomarkers, and selected five patents we find relevant.
Results: Over the last few years, identification of cancer harboring epidermal growth factor receptor mutations (EGFR) or chromosomal rearrangements of anaplastic lymphoma kinase (ALK) led to new ways in classifying and treating NSCLC. On the other hand, acquired resistance are a constantly challenge in the management of patients with these mutations and new drugs options are in development to improve and amplify treatment strategies.
Conclusions: Currently, EGFR TKIs (e.g.: erlotinib, gefitinib, osimertinib) and ALK inhibitors (crizotinib, ceritinib, alectinib) provided a new face for advanced NSCLC outcomes. To understand the disease molecular profile is mandatory to define the best approach for each patient.
Export Options
About this article
Cite this article as:
De Mello Andrade Ramon*, Liu J. J. Davi, Aguiar N. Pedro and Tadokoro Hakaru, EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer, Recent Patents on Anti-Cancer Drug Discovery 2016; 11 (4) . https://dx.doi.org/10.2174/1574892811666160803090944
DOI https://dx.doi.org/10.2174/1574892811666160803090944 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From Nucleic Acids to Drug Discovery: Nucleobases as Emerging Templates for Drug Candidates
Current Medicinal Chemistry Prediction of MicroRNA–disease Associations by Matrix Completion
Current Proteomics Polyphenols of Carménère Grapes
Mini-Reviews in Organic Chemistry A Retrospective Study on <i>Gloriosa superba</i> and Its Main Active Constituents
The Natural Products Journal Folate Nutrigenetics: A Convergence of Dietary Folate Metabolism, Folic Acid Supplementation, and Folate Antagonist Pharmacogenetics
Drug Metabolism Letters Structure-activity Relationship Studies of New Marine Anticancer Agents and their Synthetic Analogues
Current Medicinal Chemistry N-Hydroxyguanidines as Substrates of Nitric Oxide Synthases
Current Topics in Medicinal Chemistry Cancer Vaccines: Emphasis on Pediatric Cancers
Current Pharmaceutical Design Role of Metabolic Enzymes P450 (CYP) on Activating Procarcinogen and their Polymorphisms on the Risk of Cancers
Current Drug Metabolism Solid Lipid Nanoparticles Containing Nimesulide: Preparation, Characterization and Cytotoxicity Studies
Current Nanoscience Cucurbitacin IIb from Ibervillea sonorae Induces Apoptosis and Cell Cycle Arrest via STAT3 Inhibition
Anti-Cancer Agents in Medicinal Chemistry Molecules of Parasites as Immunomodulatory Drugs
Current Topics in Medicinal Chemistry Local Drug Delivery Based Treatment Approaches for Effective Management of Periodontitis
Current Drug Therapy PET Radiopharmaceuticals for Personalized Medicine
Current Drug Targets Novel Glycomimetics: Anomeric and N-Glycosyl Sulfonamides
Current Organic Chemistry Targeting the Folate Receptor: Effects of Conjugating Folic Acid to DOX Loaded Polymeric Micelles
Anti-Cancer Agents in Medicinal Chemistry Discovery of Hedgehog Antagonists for Cancer Therapy
Current Medicinal Chemistry Nanocarriers for Respiratory Diseases Treatment: Recent Advances and Current Challenges
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Anticancer Platinum Complexes - State of the Art and Future Prospects (Guest Editor: Markus Galanski)]
Anti-Cancer Agents in Medicinal Chemistry Anti-Cancer/Anti-Tumor
Current Bioactive Compounds